An early clinical trial of daraxonrasib has reported tumour responses in patients with pancreatic cancer, a disease with limited treatment options. Researchers say the findings warrant further investigation, but longer studies are needed to establish whether the treatment extends survival and how long its effects can last in these patients.
The phase I/II trial found that tumours stopped growing in 90% of patients. Just over 60% experienced tumour shrinkage or disappearance, while around 8% had no detectable tumours on CT scans. Patients were followed for an average of approximately 18 months, with some remaining free of recurrence during that period.
Daraxonrasib targets RAS mutations, which help drive tumour growth and are present in most pancreatic cancers. Similar mutations occur in other cancers, including lung and ovarian cancers. Researchers hope the approach could eventually benefit additional patient groups, although the findings described here do not establish its effectiveness in those diseases.
Dr Wungki Park, of Memorial Sloan Kettering Cancer Center, reported higher response rates, greater tumour reductions and nearly twice the duration of disease control. He said these improvements might translate into longer survival. However, that possibility remains to be confirmed through further research and follow-up of patients receiving the treatment.
Cancer Research UK described the results as a major advance. Its representative, Dr Sam Godfrey, said progress against pancreatic cancer had been overdue, while stressing that clear scans do not necessarily mean someone is cancer-free. Conference chair Professor Elena Garralda also highlighted potential improvements in survival and delayed tumour progression.
Pancreatic cancer has the lowest survival rate among common cancers in the UK. The report cites approximately 11,500 diagnoses and 10,200 deaths annually in Britain, alongside an estimated 53,000 deaths in the United States. For patients with advanced disease, researchers hope treatment advances will provide more time, even without cure.